<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35524479</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1745-1701</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Schizophrenia bulletin</Title>
          <ISOAbbreviation>Schizophr Bull</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">sbac039</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbac039</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND HYPOTHESIS" NlmCategory="OBJECTIVE">Optimal doses of most antipsychotics in the maintenance treatment of schizophrenia are unknown. We aimed to study the risk of severe relapse indicated by rehospitalization for different dose categories of 15 most frequently used antipsychotics in monotherapy in Finland.</AbstractText>
          <AbstractText Label="STUDY METHODS" NlmCategory="METHODS">We studied the risk of rehospitalization (Adjusted Hazard Ratio, aHR) associated with six antipsychotic monotherapy dose categories (as time-varying dose, measured in defined daily dose, DDDs/day) in a nationwide cohort of persons diagnosed with schizophrenia (n = 61 889), using within-individual analyses to eliminate selection bias.</AbstractText>
          <AbstractText Label="STUDY RESULTS" NlmCategory="RESULTS">Among the 15 most widely used antipsychotics, 13 had a U- or J-shaped dose-response curve, showing the lowest risks of relapse for doses of 0.6-&lt;1.1 DDDs/day vs nonuse of antipsychotics. The exceptions were oral perphenazine (aHR = 0.72, 95% CI = 0.68-0.76, &lt;0.6 DDDs/day), and olanzapine-long-acting injectable (LAI), which had the lowest aHR of any antipsychotic (aHR = 0.17, 95% CI = 0.11-0.25, 1.4-&lt;1.6 DDDs/day). Certain risperidone and perphenazine doses &lt;0.9 DDD/day were associated with 21%-45% lower risk of rehospitalization (P &lt; .001) than the standard dose of 0.9-1.1 DDD/day (ie, 5 mg for risperidone and 30 mg for perphenazine).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For most antipsychotics, the risk of severe relapse was the lowest during use of standard dose. Our results suggest that olanzapine LAI is highly effective in dose ranges &gt;0.9 DDD/day, and especially at 1.4-&lt;1.6 DDDs/day (405 mg/4 weeks) associated with substantially lower risk of rehospitalization than any dose of any other antipsychotic. The current WHO standard dose definitions appear to be clearly too high for perphenazine and somewhat too high for risperidone.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Taipale</LastName>
            <ForeName>Heidi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, University of Eastern Finland, Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Psychiatry Research, Stockholm City Council , Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanskanen</LastName>
            <ForeName>Antti</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Psychiatry Research, Stockholm City Council , Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Population Health Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luykx</LastName>
            <ForeName>Jurjen J</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>GGNet Mental Health, Warnsveld, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Solmi</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-4877-7233</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Mental Health, The Ottawa Hospital, Ottawa, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ottawa Hospital Research Institute (OHRI), Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leucht</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-4934-4352</Identifier>
            <AffiliationInfo>
              <Affiliation>Section Evidence Based Medicine in Psychiatry and Psychotherapy, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, München, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Correll</LastName>
            <ForeName>Christoph U</ForeName>
            <Initials>CU</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tiihonen</LastName>
            <ForeName>Jari</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-0400-6798</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Psychiatry Research, Stockholm City Council , Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neuroscience Center, University of Helsinki, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Schizophr Bull</MedlineTA>
        <NlmUniqueID>0236760</NlmUniqueID>
        <ISSNLinking>0586-7614</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">hospitalization</Keyword>
        <Keyword MajorTopicYN="N">prevention</Keyword>
        <Keyword MajorTopicYN="N">psychosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>3</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35524479</ArticleId>
        <ArticleId IdType="doi">10.1093/schbul/sbac039</ArticleId>
        <ArticleId IdType="pii">6582123</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
